XORTX Therapeutics (XORTX Therapeutics) Price-to-Tangible-Book : 0.98 (As of Apr. 25, 2024)

View and export this data going back to 2018. Start your Free Trial

What is XORTX Therapeutics Price-to-Tangible-Book?

As of today (2024-04-25), XORTX Therapeutics's share price is $2.9018. XORTX Therapeutics's Tangible Book per Share of Sep. 2023 for the quarter that ended in Sep. 2023 was $2.96. Hence, XORTX Therapeutics's Price to Tangible Book Ratio of today is 0.98.

The historical rank and industry rank for XORTX Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

XRTX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.95 Med: 6.14 Max: 228.93
Current: 0.97

During the past 8 years, XORTX Therapeutics's highest Price to Tangible Book Ratio was 228.93. The lowest was 0.95. And the median was 6.14.

XRTX's Price-to-Tangible-Book is ranked better than
82.84% of 1218 companies
in the Biotechnology industry
Industry Median: 2.69 vs XRTX: 0.97

A closely related ratio is called PB Ratio. As of today, XORTX Therapeutics's share price is $2.9018. XORTX Therapeutics's Book Value per Sharefor the quarter that ended in Sep. 2023 was $3.05. Hence, XORTX Therapeutics's P/B Ratio of today is 0.95.

XORTX Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for XORTX Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XORTX Therapeutics Price-to-Tangible-Book Chart

XORTX Therapeutics Annual Data

Trend

Feb15

Feb16

Feb17

Dec18

Dec19

Dec20

Dec21

Dec22

Price-to-Tangible-Book

Get a 7-Day Free Trial

215.55

11.75

2.06

1.79

XORTX Therapeutics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Price-to-Tangible-Book	Get a 7-Day Free Trial															2.06	1.79	0.94	1.61	1.82

Competitive Comparison of XORTX Therapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, XORTX Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

XORTX Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XORTX Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where XORTX Therapeutics's Price-to-Tangible-Book falls into.

XORTX Therapeutics Price-to-Tangible-Book Calculation

XORTX Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Sep. 2023 )
	=	2.9018	/	2.959
	=	0.98

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

XORTX Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of XORTX Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

XORTX Therapeutics (XORTX Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XORTX Therapeutics Inc (NAS:XRTX) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

ANUA:Germany XRTX:Canada

Address

3710 - 33rd Street NW, Calgary, AB, CAN, T2L 2M1

Website

https://www.xortx.com

XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.